共 50 条
Improvement of survival and prospect of cure in patients with metastatic breast cancer
被引:59
|作者:
Cheng, Yee Chung
[3
]
Ueno, Naoto T.
[1
,2
]
机构:
[1] Univ Texas MD Anderson Canc Ctr, Breast Canc Translat Res Lab, Dept Breast Med Oncol & Stem Cell Transplantat, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Cellular Therapy, Houston, TX 77030 USA
[3] Med Coll Wisconsin, Dept Med, Div Hematol & Oncol, Milwaukee, WI 53226 USA
基金:
美国国家卫生研究院;
关键词:
Metastatic breast cancer;
Chemotherapy;
Targeted therapy;
Radiation therapy;
Surgery;
HIGH-DOSE CHEMOTHERAPY;
STEM-CELL TRANSPLANTATION;
LONG-TERM SURVIVAL;
HEPATIC ARTERIAL INFUSION;
DISEASE-FREE SURVIVAL;
LIVER METASTASES;
BRAIN METASTASES;
RADIOFREQUENCY ABLATION;
SURGICAL-TREATMENT;
PROGNOSTIC-FACTORS;
D O I:
10.1007/s12282-011-0276-3
中图分类号:
R73 [肿瘤学];
学科分类号:
100214 ;
摘要:
Patients with metastatic breast cancer have traditionally been considered incurable with conventional treatment. However, 5-10% of those patients survive more than 5 years, and 2-5% survive more than 10 years. Recent studies suggest that the survival of patients with metastatic breast cancer has been slowly improving. In this review, we examine the possible curative approach for a certain group of patients with metastatic breast cancer. We identify that patients most likely to benefit from such an aggressive approach are young and have good performance status, adequate body functional reserve, long disease-free interval before recurrence, oligometastatic disease, and low systemic tumor load. An aggressive multidisciplinary approach including both local treatment of macroscopic disease and systemic treatment of microscopic disease can result in prolonged disease control in certain patients with metastatic breast cancer. Whether patients with prolonged disease control are "cured" remains controversial.
引用
收藏
页码:191 / 199
页数:9
相关论文